Evidence map›Paper›PMID 37093942›Full record

ArticleRevista colombiana de obstetricia y ginecologia2023

Primary breast B-cell non-Hodgkin’s lymphoma of the breast. Case Report and review of the literature

Leopoldo Santiago-Sanabria, Julieta Garza-Arrieta, Gina Daniela Porras-Ibarra, Montserrat Malfavón-Farias

Abstract read
In one paragraph

Article in Revista colombiana de obstetricia y ginecologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leopoldo Santiago-SanabriaHospital Ángeles Lomas, Huixquilican, Estado de México (México).. leopoldosantiagosanabria@gmail.com.ORCID 0000-0002-6287-5932
Julieta Garza-ArrietaHospital Ángeles Lomas, Huixquilican, Estado de México (México).. drajulie04@gmail.com.ORCID 0000-0003-1090-2027
Gina Daniela Porras-IbarraHospital Ángeles Lomas, Huixquilican, Estado de México (México).. draporras@hotmail.com.ORCID 0000-0003-4427-9149
Montserrat Malfavón-FariasHospital ABC, Santa Fe, Cuajimalpa, Ciudad de México (México).. montse.malfavon@gmail.com.ORCID 0000-0002-6428-4001

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To report a case of primary breast B-cell non-Hodgkin’s lymphoma (PBL) and to conduct a literature review of its diagnosis and treatment. Materials and methods: Case report of an 80-year-old female patient who presented to a private referral institution in Mexico, with PBL. She was also diagnosed with primary liver melanoma by means of targeted biopsy and pathology testing. The patient received treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), quadrantectomy, lymph node dissection and radiotherapy. The PBL showed good response but, because of progression of the second primary tumor, the patient went on to receive palliative care. A review of the literature was conducted in Medline via PubMed, LILACS and Google Scholar. Cohort studies, case reports and case series in patients with PBL that discussed diagnosis, treatment and prognosis of this disease, published in English and Spanish between 2000 and 2022, were included. Results: Overall, 23 titles were identified, of which 17 consisting of case reports and case series met the inclusion criteria. The majority of patients received R-CHOP as chemotherapy regimen, with irradiation as adjunct therapy. Close to 80 % went into complete remission. The most frequent site of recurrence was the central nervous system. Five-year survival was 83.6 % in the included studies. Conclusions: At present, the CHOP regimen, with or without rituximab and usually accompanied by radiotherapy, is the most widely used and the only one that has shown a positive impact on survival. Additional randomized clinical trials are needed in order to gain a clearer insight into the effectiveness and safety of these treatments.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Non-HodgkinAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansMexicoPrednisoneRituximabTreatment OutcomeVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristinebreast cancercase reportmalignant neoplasm of the breastNon-Hodgkin’s lymphomaprognostic factors

Identifiers

PMID37093942
PMCPMC10174716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.